The Weekly Pulse — Edition 18, January 25, 2026

Published · Researched 2026-09-22

Good Signal's weekly digest: the best verified news of the week of January 19, 2026.

The week in one paragraph

The defining image of the week was a trio crossing the Boston Marathon finish line as one. At the 130th Boston Marathon on April 20, 2026, Ajay Haridasse, a 21-year-old local college student, collapsed four times about a thousand feet from the finish on Boylston Street. Dozens of runners passed him — then Aaron Beggs, a former Army corporal from Bangor, Northern Ireland, and Robson De Oliveira of Brazil stopped their own races, slung Haridasse's arms over their shoulders, and carried him across. Beggs still finished in 2:44:36, placing 1,884th of nearly 30,000 runners. Haridasse later told the Boston Herald that after his fourth fall he was getting ready to crawl; Beggs told the BBC that stopping was simply natural instinct; De Oliveira told the BBC he had thought himself too spent to help alone, but decided that if someone else stopped, he would stop too. The fan video — originally credited to an Instagram account, then everywhere — circulated across TikTok, YouTube, and LinkedIn. Sportsmanship, at pace.

Rising

Gene therapy had a remarkable week. A Nature Medicine study published June 5, 2024 reported that bilateral OTOF gene therapy restored hearing in all five children in its initial cohort — with improved speech perception and sound localization, and no serious adverse events. The results are circulating via science communicators on Threads. Meanwhile, Daniel Cressy, 23, of Metairie, Louisiana, became the first person in Louisiana and the Gulf South to be functionally cured of sickle cell disease: his stem cells were collected from July 30, 2025, edited in Scotland with the CRISPR therapy Casgevy, and infused on March 18, 2026 at Manning Family Children's Hospital in New Orleans. Discharged in mid-April, he now has the highest hemoglobin of his life, has had no crises since, and is pursuing his dream of becoming a pilot. Louisiana Medicaid covered the roughly $2.2 million drug cost after a two-year approval process. On July 1, 2026, the FDA expanded Casgevy to children aged 2 to 11 — the first CRISPR therapy approved for young children with the disease. Still watching: a WHO children's sickle-cell guideline was observed only via a Threads post, and pediatric trial subgroup figures conflict across secondary sources.

Big cats and sea eagles, coming back. WWF Nepal reported on July 29, 2026 that the national tiger census estimated 429 tigers — up from 355 in 2022, across five protected areas surveyed by camera trap. Nepal has nearly doubled its tiger population in a decade and a half. In England, three white-tailed eagle chicks hatched in the wild in 2026 as part of the Isle of Wight reintroduction that began in 2019 — the species extinct as an English breeding bird since the late 18th century, now breeding on its own. Still watching: fledging success for the three chicks isn't confirmed, and the per-park tiger breakdown wasn't published.

Falling

The idea that sickle cell is a life sentence. A one-time treatment that ends pain crises for eligible patients — and is now approved for toddlers — turns a lifetime diagnosis into a solvable problem. Coverage getting the $2.2 million covered matters as much as the science.

The assumption that tigers only decline. Nepal is far ahead of the global goal of doubling wild tigers. Protected areas, camera traps, patience: the recipe works.

Quiet signals

OTOF's social layer is thin. The hearing-restoration results are circulating via science accounts, but direct patient-community posts weren't observed in the research pass — watch whether families and clinicians pick this up. Early/uncertain.

Eagle fledging unconfirmed. Three chicks hatched is the milestone; whether all three fledged is still watching.

Sickle-cell pediatric numbers. The FDA expansion is verified; the exact trial subgroup figures reported in secondary coverage conflict — don't repeat a denominator without a primary source. Still watching.

Scoreboard

N/A — editions written out of sequence; no prior calls to grade.

One line to close

Two strangers chose a person over a finish time, and medicine kept rewriting diagnoses — a week that rewarded showing up.